Transcriptional profiling of azole-resistant Candida parapsilosis strains

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3546-3556

  Silva, A P ^a   Miranda, I M ^a   Guida, A ^b   Synnott, J ^b   Rocha, R ^a   Silva, R ^c   Amorim, A ^c   Pina Vaz, C ^a,d   Butler, G ^b   Rodrigues, A G ^a  

^a University of Porto   (Portugal)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF PORTO   (Portugal)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE 5; CITRATE SYNTHASE; CITRATE SYNTHASE 1; DAG7 PROTEIN; ERGOSTEROL; FLUCONAZOLE; GRP2 PROTEIN; HSX11 PROTEIN; KRE1 PROTEIN; LAP4 PROTEIN; LPG20 PROTEIN; MNT2 PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OXIDOREDUCTASE; OYE32 PROTEIN; PAG6 PROTEIN; PDR16 PROTEIN; PHOSPHOLIPASE B3; PMA1 PROTEIN; POSACONAZOLE; RPA190 PROTEIN; SECRETED ASPARTYL PROTEINASE 7; STP4 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MRR1; TRANSCRIPTION FACTOR NDT80; TRANSCRIPTION FACTOR UPC2; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; FUNGAL STRAIN; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC TRANSCRIPTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; POINT MUTATION; PRIORITY JOURNAL; STEROL SYNTHESIS; UPREGULATION;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION PROFILING; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIAZOLES;

EID: 79959214576     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01127-10     Document Type: Article

References (80)

1. Akins, R. A. 2005. An update on antifungal targets and mechanisms of resistance in Candida albicans. Med. Mycol. 43:285-318.
2. Alarco, A. M., and M. Raymond. 1999. The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans. J. Bacteriol. 181:700-708. (Pubitemid 29061549)
3. Albertson, G. D., M. Niimi, R. D. Cannon, and H. F. Jenkinson. 1996. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents Chemother. 40:2835-2841.
4. Almirante, B., et al. 2006. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 44:1681-1685. (Pubitemid 43726255)
5. Andes, D., et al. 2006. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob. Agents Chemother. 50:2374-2383.
6. Andes, D., A. Lepak, J. Nett, L. Lincoln, and K. Marchillo. 2006. In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling. Antimicrob. Agents Chemother. 50:2384-2394.
7. Arbour, M., et al. 2009. Widespread occurrence of chromosomal aneuploidy following the routine production of Candida albicans mutants. FEMS Yeast Res. 9:1070-1077.
8. Azanza, J. R., E. Garcia-Quetglas, and B. Sadaba. 2007. Pharmacology of azoles. Rev. Iberoam. Micol. 24:223-227. (In Spanish.)
9. Barchiesi, F., et al. 2000. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob. Agents Chemother. 44:1578-1584.
10. Barker, K. S., et al. 2004. Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J. Antimicrob. Chemother. 54:376-385.
11. Butler, G., et al. 2009. Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature 459:657-662.
12. Cannon, R. D., et al. 2009. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22:291-321.
13. Chen, S. C., E. G. Playford, and T. C. Sorrell. 2010. Antifungal therapy in invasive fungal infections. Curr. Opin. Pharmacol. 10:522-530.
14. Cheung, C., Y. Guo, P. Gialanella, and M. Feldmesser. 2006. Development of candidemia on caspofungin therapy: a case report. Infection 34:345-348. (Pubitemid 44968928)
15. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Third informational supplement: document M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Costa-de-Oliveira, S., C. Pina-Vaz, D. Mendonca, and A. Goncalves Rodrigues. 2008. A first Portuguese epidemiological survey of fungaemia in a university hospital. Eur. J. Clin. Microbiol. Infect. Dis. 27:365-374.
18. Coste, A. T., M. Karababa, F. Ischer, J. Bille, and D. Sanglard. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell 3:1639-1652. (Pubitemid 40025121)
19. De Backer, M. D., et al. 2001. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob. Agents Chemother. 45:1660-1670.
20. De Deken, X., and M. Raymond. 2004. Constitutive activation of the PDR16 promoter in a Candida albicans azole-resistant clinical isolate overexpressing CDR1 and CDR2. Antimicrob. Agents Chemother. 48:2700-2703.
21. Do, J. H., and D. K. Choi. 2008. Clustering approaches to identifying gene expression patterns from DNA microarray data. Mol. Cells 25:279-288.
22. Dunkel, N., J. Blass, P. D. Rogers, and J. Morschhauser. 2008. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69:827-840.
23. Dunkel, N., et al. 2008. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot. Cell 7:1180-1190. (Pubitemid 351969332)
24. Edgar, F. C. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32:1792-1797.
25. Fitzpatrick, D. A., P. O'Gaora, K. P. Byrne, and G. Butler. 2010. Analysis of gene evolution and metabolic pathways using the Candida Gene Order Browser. BMC Genomics 11:290.
26. Garcia San Miguel, L., et al. 2004. Morphotypic and genotypic characterization of sequential Candida parapsilosis isolates from an outbreak in a pediatric intensive care unit. Diagn. Microbiol. Infect. Dis. 49:189-196.
27. Heilmann, C. J., S. Schneider, K. S. Barker, P. D. Rogers, and J. Morschhauser. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob. Agents Chemother. 54:353-359.
28. Hitchcock, C. A., K. J. Barrett-Bee, and N. J. Russell. 1986. The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J. Gen. Microbiol. 132:2421-2431.
29. Hof, H. 2008. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist Updat. 11:25-31.
30. Hoffman, C. S., and F. Winston. 1987. A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli. Gene 57:267-272. (Pubitemid 18007116)
31. Hooshdaran, M. Z., et al. 2004. Proteomic analysis of azole resistance in Candida albicans clinical isolates. Antimicrob. Agents Chemother. 48:2733-2735.
32. Hwang, C. S., et al. 2002. Copper- and zinc-containing superoxide dismutase (Cu/ZnSOD) is required for the protection of Candida albicans against oxidative stresses and the expression of its full virulence. Microbiology 148:3705-3713.
33. Karababa, M., A. T. Coste, B. Rognon, J. Bille, and D. Sanglard. 2004. Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob. Agents Chemother. 48:3064-3079.
34. Kuhn, D. M., et al. 2004. Candida parapsilosis characterization in an outbreak setting. Emerg. Infect. Dis. 10:1074-1081.
35. Kusch, H., et al. 2004. A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains. Mol. Genet. Genomics 271:554-565.
36. Li, X., et al. 2004. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J. Antimicrob. Chemother. 53:74-80.
37. Liu, T. T., et al. 2005. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob. Agents Chemother. 49:2226-2236.
38. Marr, K. A., C. N. Lyons, T. R. Rustad, R. A. Bowden, and T. C. White. 1998. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob. Agents Chemother. 42:2584-2589.
39. Marr, K. A., C. N. Lyons, K. Ha, T. R. Rustad, and T. C. White. 2001. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob. Agents Chemother. 45:52-59.
40. Morschhauser, J. Regulation of multidrug resistance in pathogenic fungi. Fungal Genet. Biol. 47:94-106.
41. Morschhauser, J., et al. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3:e164.
42. Pfaller, M. A., et al. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
43. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
44. Pfaller, M. A., and D. J. Diekema. 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10(Suppl. 1):11-23.
45. Pfaller, M. A., et al. 2008. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46:842-849. (Pubitemid 351379967)
46. Pfaller, M. A., et al. 2000. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob. Agents Chemother. 44:747-751.
47. Pinto e Silva, A. T., S. Costa-de-Oliveira, A. Silva-Dias, C. Pina-Vaz, and A. G. Rodrigues. 2009. Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles. FEMS Yeast Res. 9:626-633.
48. Posteraro, B., et al. 2004. Candida parapsilosis bloodstream infection in pediatric oncology patients: results of an epidemiologic investigation. Infect. Control Hosp. Epidemiol. 25:641-645.
49. Prasad, R., N. A. Gaur, M. Gaur, and S. S. Komath. 2006. Efflux pumps in drug resistance of Candida. Infect. Disord. Drug Targets 6:69-83.
50. Prasad, T., A. Chandra, C. K. Mukhopadhyay, and R. Prasad. 2006. Unexpected link between iron and drug resistance of Candida spp.: iron depletion enhances membrane fluidity and drug diffusion, leading to drug-susceptible cells. Antimicrob. Agents Chemother. 50:3597-3606.
51. Protchenko, O., R. Rodriguez-Suarez, R. Androphy, H. Bussey, and C. C. Philpott. 2006. A screen for genes of heme uptake identifies the FLC family required for import of FAD into the endoplasmic reticulum. J. Biol. Chem. 281:21445-21457.
52. Ramanan, N., and Y. Wang. 2000. A high-affinity iron permease essential for Candida albicans virulence. Science 288:1062-1064. (Pubitemid 30324240)
53. Rees, E. M., J. Lee, and D. J. Thiele. 2004. Mobilization of intracellular copper stores by the ctr2 vacuolar copper transporter. J. Biol. Chem. 279:54221-54229.
54. Riggle, P. J., and C. A. Kumamoto. 2000. Role of a Candida albicans P1-type ATPase in resistance to copper and silver ion toxicity. J. Bacteriol. 182:4899-4905.
55. Riggle, P. J., and C. A. Kumamoto. 2006. Transcriptional regulation of MDR1, encoding a drug efflux determinant, in fluconazole-resistant Candida albicans strains through an Mcm1p binding site. Eukaryot. Cell 5:1957-1968.
56. Rogers, P. D., and K. S. Barker. 2003. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob. Agents Chemother. 47:1220-1227.
57. Rossignol, T., et al. 2009. Correlation between biofilm formation and the hypoxic response in Candida parapsilosis. Eukaryot. Cell 8:550-559.
58. Rossignol, T., et al. 2007. Transcriptional response of Candida parapsilosis following exposure to farnesol. Antimicrob. Agents Chemother. 51:2304-2312.
59. Ruhnke, M., A. Schmidt-Westhausen, and J. Morschhauser. 2000. Development of simultaneous resistance to fluconazole in Candida albicans and Candida dubliniensis in a patient with AIDS. J. Antimicrob. Chemother. 46:291-295.
60. Sandven, P. 2000. Epidemiology of candidemia. Rev. Iberoam. Micol. 17:73-81.
61. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
62. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
63. Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
64. Sarvikivi, E., et al. 2005. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J. Clin. Microbiol. 43:2729-2735.
65. Schubert, S., P. D. Rogers, and J. Morschhauser. 2008. Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains. Antimicrob. Agents Chemother. 52:4274-4280.
66. Sellam, A., F. Tebbji, and A. Nantel. 2009. Role of Ndt80p in sterol metabolism regulation and azole resistance in Candida albicans. Eukaryot. Cell 8:1174-1183.
67. Silva, A. P., I. M. Miranda, C. Lisboa, C. Pina-Vaz, and A. G. Rodrigues. 2009. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J. Clin. Microbiol. 47:2392-2397.
68. Smyth, G. K., and T. Speed. 2003. Normalization of cDNA microarray data. Methods 31:265-273.
69. van Asbeck, E., K. V. Clemons, M. Martinez, A. J. Tong, and D. A. Stevens. 2008. Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn. Microbiol. Infect. Dis. 62:106-109.
70. van den Hazel, H. B., H. Pichler, M. A. do Valle Matta, E. Leitner, A. Goffeau, and G. Daum. 1999. PDR16 and PDR17, two homologous genes of Saccharomyces cerevisiae, affect lipid biosynthesis and resistance to multiple drugs. J. Biol. Chem. 274:1934-1941.
71. Vermitsky, J. P., and T. D. Edlind. 2004. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob. Agents Chemother. 48:3773-3781.
72. Wakiec, R., et al. 2007. Voriconazole and multidrug resistance in Candida albicans. Mycoses 50:109-115.
73. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
74. Wingard, J. R., et al. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.
75. Wingard, J. R., et al. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.
76. Xiao, L., et al. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48:568-574.
77. Xu, Z., et al. 2006. cDNA microarray analysis of differential gene expression and regulation in clinically drug-resistant isolates of Candida albicans from bone marrow transplanted patients. Int. J. Med. Microbiol. 296:421-434.
78. Yan, L., et al. 2008. DNA microarray analysis of fluconazole resistance in a laboratory Candida albicans strain. Acta Biochim. Biophys. Sin. (Shanghai) 40:1048-1060.
79. Zahurak, M., et al. 2007. Pre-processing Agilent microarray data. BMC Bioinform. 8:142.
80. Znaidi, S., et al. 2007. The zinc cluster transcription factor Tac1p regulates PDR16 expression in Candida albicans. Mol. Microbiol. 66:440-452.